CardiNor Test for Cardiovascular Disease Biomarker Gains CE Mark

March 18, 2022

Norwegian company CardiNor has received a CE mark for its enzyme-linked immunosorbent assay (ELISA) test for secretoneurin, a biomarker for cardiovascular disease.

The biomarker is a neuropeptide detectable in the blood stream that is produced by neuroendocrine and heart muscle cells. It is a strong predictor of mortality in patients with ventricular arrhythmia, acute heart failure and in acute respiratory failure patients with cardiovascular disease and severe sepsis.

CardiNor says it has demonstrated secretoneurin’s potential clinical value in two specific areas — support of patient selection for implantable cardioverter defibrillators and heart failure patient discharge eligibility.

View today's stories